Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Scientific News Boston Scientific Resumes Farapulse Pulsed Field Ablation Study In First Line Afib is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Boston Scientific Corp (BSX) Secures FDA Labeling Expansion for FARAPULSE Pulsed Field Ablation (PFA) System

Boston Scientific Corporation (NYSE:BSX) is one of Goldman Sachs’ top healthcare stock picks. On July 7, Boston Scientific (NYSE:BSX) saw its shares rise as TD Cowen reaffirmed its Buy rating and $115 ... Read More
“Puzzling”: Farapulse trial investigator on the device’s use beyond recommendations
One-year data from Boston Scientific’s FARADISE registry demonstrated the strong efficacy of its Farapulse PFA system yet also revealed that some users are ablating more targets than necessary. Read More
Newer pulsed field ablation ‘already as effective’ as radiofrequency ablation
Pulsed field ablation demonstrated similarly durable atrial fibrillation ablation as radiofrequency ablation, with fewer procedure-related adverse events and shorter procedure time, researchers ... Read More
Dr. Steven Mickelsen launches new minimally invasive ablation tech company Del Medtech
Dr. Steven Mickelsen, a pioneer in the pulsed field ablation (PFA) space, today announced the launch of his new venture, Del Medtech. Read More
Kardium receives FDA OK for pulsed field ablation system

The company raised $250 million in July to expand its manufacturing capabilities and establish multiple teams to support the launch. Read More
BEAT PAROX-AF: Pulsed-Field Ablation Not Superior to Radiofrequency
Increases in procedural speed and safety, however, support the continuing shift to the newer modality, one expert says. Read More
Pulse wins IDE approval; Galvanize pulls in $100M
Pulse Biosciences will study PFA in cardiac surgery. Meanwhile, Galvanize Therapeutics also named a new CEO, and PFA pioneer Steven Mickelsen has launched another company. Read More
Boston Scientific Presses Its Advantage in Pulsed Field Ablation

Boston Scientific has proven itself to be a fierce competitor among three major cardiac device makers, with a track record of meaningful innovation and impressive operational chops. Even a prolonged ... Read More
Blow Us A Whistle

Comments (Whistles) Designed By Disqus